sub:provenance { beldoc:dce:description "Approximately 61,000 statements." ; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ; dce:title "BEL Framework Large Corpus Document" ; pav:authoredBysub:_6 ; pav:version "20131211" . sub:_5prov:value "Extending our prior reports that intravenous (IV) administration of the sphingolipid angiogenic factor, sphingosine 1-phosphate (S1P), attenuates inflammatory lung injury and vascular permeability via ligation of S1PR1, we now determine that direct intratracheal (IT) or intravenous (IV) administration of S1P, or a selective S1PR1 agonist (SEW- 2871), produces highly concentration-dependent barrier-regulatory responses in the murine lung. IT or IV administration of S1P or SEW-2871 at <0.3 mg/kg was protective against LPS-induced murine lung inflammation and permeability," ; prov:wasQuotedFrompubmed:19749179 . sub:_6rdfs:label "Selventa" . sub:assertionprov:hadPrimarySourcepubmed:19749179 ; prov:wasDerivedFrombeldoc: , sub:_5 . }